Noah Britt was 14 and living in Bloomington, Indiana, when he was diagnosed with acute myeloid leukemia in August 2025 [2]. Chemotherapy did not do what it was supposed to do. In January 2026 he received a stem cell transplant from a living donor found through the National Marrow Donor Program. Between days 14 and 21 he ran high fevers. By day 28 there was no evidence that the donor cells had engrafted [1].
There was no second match on the registry for him.
In February 2026, physicians at Riley Hospital for Children transplanted cryopreserved bone marrow recovered from a consented deceased organ donor [2]. He is in remission.
This is worth stating precisely, because we filed it wrong the first time. Our wire brief described this case as CAR-T therapy. It is not CAR-T, which re-engineers a patient's own immune cells and puts them back. This is an allogeneic bone marrow stem cell transplant, the same procedure Noah had in January, with the marrow sourced from a person who had died and consented to organ donation rather than from a living volunteer. The correction is ours to make and this piece is where we make it.
The marrow came through Ossium Health's HOPE Program, which the company describes as "an expanded-access arm of the PRESERVE I clinical trial" and which "provides cryopreserved hematopoietic progenitor cell (HPC) marrow to patients ages 12 to 80 who urgently need a transplant but are unable to find a suitable living donor match" [2]. Twenty-eight patients worldwide have received transplants using the technology [2].
The argument for banked marrow is entirely about the clock. Dr. Jodi Skiles, medical director of Riley's pediatric stem cell transplant program, put it in one sentence: "Because these stem cells are banked and ready to use, we were able to act in days instead of months" [2]. Ossium "is able to get bone marrow shipped and transplanted in 30 hours" [1]. Some patients on banked marrow begin producing healthy new blood cells in as little as 17 days [2].
How long the alternative would have taken depends on which account you read, and the two do not agree. Indiana Public Media reported that for Noah, "another living donor stem cell transplant would take up to six weeks" [1]. WBIW, reporting the same case, wrote that "traditional donor searches can take months, and some patients never identify a suitable match" [2]. Six weeks and several months are different problems. We are printing both rather than splitting them.
Either way, the number Skiles was actually managing was smaller than both. Noah had no functioning immune system while he waited. "All it takes is one small infection and he could die," she said [1].
The scale of the underlying gap is not small. Roughly 18,000 Americans a year are diagnosed with blood cancers requiring a transplant, and about 4,000 of them are children [2]. Erik Woods, Ossium's chief science officer and co-founder, is explicit about what the company is aiming at: "Thousands of people every year need a transplant and don't get one, and we really believe we can fill that gap entirely" [1].
Twenty-eight patients is not filling a gap of thousands. It is a demonstration that the supply exists.
The marrow itself cost the family nothing, on a condition. Indiana Public Media reports that "through Hope, the bone marrow is free with the agreement that recipients share data with Ossium on the results" [1]. That is a reasonable arrangement for an expanded-access program and it is also a private company acquiring outcome data from patients who have no alternative. Both of those are true at once and the second one does not go away because the first one worked.
The claim that this is a world first belongs to the people who performed it. Riley Children's Health says Noah is "the first pediatric leukemia patient in the world to receive a successful stem cell transplant from a deceased donor" [1], and WBIW reported it as the world's first pediatric bone marrow stem cell transplant using cells from a deceased donor [2]. We found no independent registry, regulator or third-party body confirming the priority claim. It rests on the hospital and on Ossium, and we are attributing it to them rather than asserting it.
None of this is breaking. The coverage runs from June 16 to July 1, and the transplant was in February. We are running it now because we opened a record on this case and got the mechanism wrong, and a record you opened is a record you close. The part that holds up under every check is the simplest part: a 14-year-old in Bloomington whose registry donor failed and who had no second match is in remission, because marrow from someone who died was already in a freezer, and it reached him in 30 hours.
